NASDAQ$ALMR

Alamar Biosciences, Inc · Q1 2026 earnings

Q1 2026 earnings ·

Briefing

Alamar Biosciences, Inc Q1 fiscal 2026: $26.0M revenue, $21.3M net loss

for the year ended December 31, 2026 or for any other future annual or interim period. (SEC accession 0001193125-26-213424)

  • Revenue: $26.0M
  • Net loss: $21.3M
  • Diluted EPS: $-1.74
  • Operating income: $-12.3M
  • Gross profit: $14.5M

Headline financials

Total Revenue

$26M

No prior period
EPS

-$1.74

No prior period
Capital Expenditures

-$600K

No prior period
Free Cash Flow

-$20.9M

No prior period
Net Income

-$21.3M

No prior period
Operating Income

-$12.3M

No prior period
Gross Profit

$14.5M

No prior period
Cash & Equivalents

$64.6M

No prior period
Total Assets

$186M

No prior period

Revenue & EPS history

Alamar Biosciences, Inc · Revenue · Quarterly

$26M

Q1 2026

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro